Some think this Canadian marijuana stock is headed for an epic disaster. Here's where they're right -- and where they're wrong.
There are some marijuana stocks that seem likely to fail. But not these two.
But it's important to separate the current panic from the real potential for these biotechs.
The clock's ticking on this big pharmaceutical buyout.
They might not be household names, but these stocks offer tremendous dividends that should grab investors' attention.
Which stock wins in a battle between these two Canadian cannabis producers?
These are pretty much slam dunks for the company's upcoming quarterly update.
The big biotech thinks it just might be able to cure type 1 diabetes.
Both biotechs claim attractive dividends. But one dividend appears to be at least a little safer than the other.
One of these biotechs dominates the treatment of cystic fibrosis. The other doesn't have a single FDA-approved drug -- yet.
Which stock wins in a battle between these two top Canadian cannabis companies?
The medical technology company's flat year-over-year revenue growth doesn't tell the full story.
Investors really like the company's sneak peek at its Q4 results, which are scheduled to be officially announced next month.
Big news could be on the way.
The healthcare technology company topped Wall Street estimates on both its top and bottom lines in the third quarter.
The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.
Investors are reacting negatively to the biotech's public stock offering.
The two politicians from different parties are united on at least one front: their opposition to legalizing pot.
Yesterday's euphoria that a virus scare could boost the biotech's fortunes has given way to a more realistic assessment of what's going on.
The healthcare giant delivered a solid quarterly performance yet again, with sales growth in all of its segments.